A little more than a year ago, I gave a presentation on FDA hot topics. One of the areas that was identified in my presentation was a potential for an increase in FDA enforcement efforts relative to dietary supplements, their claims, and the issues of new drug claims. I stumbled across a posting on […]
I usually cover drug and device issues in this blog, but today, I had some “food for thought” as I read a Federal Register Notice (here), in which the FDA is asking for comment on what the term “natural” should mean when used in food products. It seems that over the years many have […]
The Office of Generic Drugs (OGD) issued MaPP 5200.7 (here) today that addresses the need for filing review for certain amendments and supplements to ANDAs. We all know that an Original ANDA must go through the filing review to determine if the ANDA is substantially complete to permit a substantive scientific review. But did you know […]
Today, at the ISPE Annual Meeting in Philadelphia, an important new tool in the battle against drug shortages will debut. The “Drug Shortages Assessment and Prevention Tool” drew on feedback from ISPE 2013 Drug Shortages Survey and 2014 Drug Shortages Prevention Plan, and focuses on the prevention and practical application to help industry assess its […]
Fran Zipp, President of Lachman Consultants, presented at the 2015 ISPE Annual Meeting, November 8-11 at the Philadelphia Marriott Downtown. She spoke about the launch of the ISPE Drug Shortage Assessment and Prevention Tool, on Monday, November 9 at 10:45 AM. For a preview of the tool, please see this article authored by Fran in […]
Last Friday, FDA published a Notice in the Federal Register (here) relative to staying a portion of its September 2013 Guidance Document titled Investigational New Drug Applications (INDs) – Determining Whether Human Research Studies Can Be Conducted Without an IND. The Agency indicated that, based on comment received on various sections of the final Guidance, they […]
How does the Office of Generic Drugs (OGD) make a determination to revise an existing bioequivalence (BE) guidance? What happens to the requirements for drug product under development or those products that are approved when a BE guidance is revised? These questions were addressed by Dr. Robert Lionberger and Dr. Larissa Lapteva in a session at the GPhA Fall Tech Conference.
As you know, the issue of controlled correspondence has historically been a contentious issue between the Office of Generic Drugs and the generic industry mostly related to timing of the response. The situation is not different today but the contention addressed today is more about the new definition of controlled correspondence and who may submit them.
Dr. Kathleen Uhl (Cook), Director Office of Generic Drugs (OGD), provided an excellent update on OGD’s progress under GDUFA. There were a number of interesting charts that described approvals, receipts and actions that defined what Cook called the “In Box” (what’s coming into OGD) and “Out Box” (productivity or what is going out of OGD).
I just received an update for the October approval numbers from OGD and the full approvals have been revised upward from 49 to 51.
